RAD-x continues German expansion - Gilde Healthcare

RAD-x continues German expansion

April 17, 2018

Utrecht, The Netherlands – Gilde Healthcare portfolio company RAD-x, the pan-European operator in diagnostic imaging, has announced that it has acquired Teleradiologisches Zentrum Koblenz (TelradKo). TelradKo provides teleradiology services to hospitals and hospital-based imaging centres in Germany. The combination with RAD-x enables TelradKo to accelerate its expansion and continue investing in the latest technology to establish itself as the leading provider of teleradiology services to small and medium sized hospitals.

 

About RAD-x

RAD-x is a fast-growing pan-European operator of diagnostic imaging centres, based on a network of local and regional centres. The network currently has a staff of over 350 healthcare professionals working in diagnostic imaging centres and hospitals. RAD-x’s growth model is based on the integration in its network of existing leading local and regional medical imaging centres and offering their radiologists to become shareholders of RAD-x. For more information, visit the company’s website at www.RAD-x.eu

About TelradKo

TelradKo is a provider of teleradiology services to hospitals and hospital-based imaging centres in Germany founded in 2014. For more information, visit the company’s website at www.telradko.de

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Benelux and Dach-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Gilde Healthcare has raised €800 million ($1 billion) for its specialized funds. For more information, visit the company’s website at www.gildehealthcare.com

More news

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
October 17, 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
October 15, 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
October 14, 2025